Early palliative care consultation for people with bone metastases referred for radiotherapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized Phase 2 trial offers patients referred for palliative radiotherapy for bone metastases a consultation with the hospital palliative care consultation team (PCCT) versus usual care. Participants are enrolled at participating Dutch centers and provide broad consent for regular questionnaires (PRESENT+) and randomization. The primary outcomes are patient-reported satisfaction with care and quality of life measured over time. Key exclusions are inability to understand Dutch, cognitive impairment, or prior contact with the hospital PCCT.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. broad informed consent for PRESENT+ (i.e., consent for filling out questionnaires at regular intervals and randomization into future intervention studies), and
2. having their treating physician in the TIPZO-RT study site (UMC Utrecht, Radboudumc or LUMC).

Exclusion Criteria:

1. not able to understand the objective of the study (in Dutch),
2. cognitive impairment or dementia, and
3. has been in contact with palliative care consultants of the hospital PCCT before.

Where it's running

• Meander MC
  Amersfoort, Netherlands Recruiting
• Groene Hart Ziekenhuis
  Gouda, Netherlands Recruiting
• Alrijne Ziekenhuis
  Leiden, Netherlands Recruiting
• Lumc
  Leiden, Netherlands Recruiting
• Radboudumc
  Nijmegen, Netherlands Recruiting

Study contacts

• Principal investigator: Yvette M. van der Linden — Leiden University Medical Center
• Study coordinator: Roxanne Gal, PhD
• Email: R.Gal@umcutrecht.nl
• Phone: +31887555555

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Analysis of outcomes and side effects in patients receiving radiation therapy

  This study looks at the results and side effects of radiation therapy in patients at Winterthur Cantonal Hospital to see how treatment can be improved for future patients.

  Recruiting Kantonsspital Winterthur KSW · Winterthur, Canton of Zurich · NCT05192876

• Primary tumor removal with targeted lymph node removal plus radiation for biliary tract cancer with lymph node spread

  This phase II study tests whether removing the main tumor and select nearby lymph nodes, followed by postoperative radiation, helps patients with biliary tract cancer and lymph node metastases.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT07893392

• Tributyrin as a dietary supplement to help prevent radiation-induced rectal injury during rectal cancer chemoradiation

  This study tests whether adding tributyrin to standard chemoradiotherapy helps prevent acute radiation-induced rectal injury in people with locally advanced rectal cancer.

  Recruiting Sixth Affiliated Hospital, Sun Yat-sen University · Guangzhou, Guangdong · NCT07802002

• Targeted Induction Therapy for Stage III Unresectable EGFR Mutant NSCLC

  This trial tests a targeted induction approach using fumetinib with platinum-based chemotherapy and concurrent radiochemotherapy in adults with unresectable stage III EGFR-mutant NSCLC to see if this combo can improve outcomes before possible surgery.

  Recruiting Phase 2 Shanghai Pulmonary Hospital, Shanghai, China · Shanghai, Shanghai Municipality · NCT07742332

• Virtual vs in-person follow-up visits after radiotherapy

  This study tests whether telehealth follow-ups during radiotherapy are practical and satisfactory for patients and physicians, compared to in-person visits.

  Recruiting Shaukat Khanum Memorial Cancer Hospital & Research Centre · Lahore, Punjab Province · NCT07724548

• Short-Course Radiotherapy Followed by CAPOX With or Without Iparomlimab and Tuvonralimab in Localized Rectal Cancer

  In people with locally advanced, treatment-naive rectal cancer, this study tests whether adding two immunotherapy drugs to a standard chemotherapy after short-course radiotherapy can improve tumor response.

  Recruiting Phase 3 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT07686640

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.